Dexcom Trial Backs Wider Use of Glucose Monitors

Dexcom has new randomized controlled trial data suggesting continuous glucose monitors (CGMs) help a broader swath of people with diabetes, not just those who depend on insulin, according to STAT News. The finding matters because reimbursement and clinical guidelines have historically reserved CGMs for insulin-using patients, leaving most people with type 2 diabetes without coverage.

If the evidence holds up, it could push payers and providers to widen access to wearable glucose sensors for patients managing their disease through diet, oral medications, or lifestyle changes. That expansion would significantly grow the addressable market for Dexcom and rivals like Abbott, whose devices are increasingly marketed to non-insulin users and even the prediabetic and wellness crowd.

The report ran alongside STAT's coverage of Apple's annual developers' conference and broader wearables momentum, a signal that consumer-grade health tracking and clinical-grade monitoring continue to converge. The open question is whether real-world outcomes and cost savings justify paying for CGMs at population scale.